Hana Initiates Marqibo Phase II Trial in Relapsed/Refractory ALL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

Hana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.

SOUTH SAN FRANCISCO, California—Hana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.

Articles in this issue
Exjade Gains Approval in EU
Study Questions the Need for Maintenance Therapy in Metastatic Colorectal Cancer
President's Cancer Panel Assesses Progress in Two Areas
Proposed Medicare OPPS Rule Draws Fire for Its 'Inadequate Reimbursement'
Cognitive Rx Reduces Depression in Breast Ca Pts
Nurses Develop Evidence-Based Guidelines for Mucositis
Anastrozole Therapy for Breast Cancer Affects Bone Health
Is Demand for Trial Subjects Outpacing Supply?
Postchemo Disappearance of Liver Mets Doesn't Mean Cure
Aromasin-Related Bone Loss Affected by Vitamin D Levels
Melanoma Mets Regress After Gene Therapy
Phase I/II Trial of AGS-003
Short Course of Preoperative Radiotherapy Improves Outcomes in Patients With Resectable Rectal Cancer
President Bush Names Niederhuber NCI Director
Lack of EGFR Expression in Colon Ca Can Be Misleading

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Related Content
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

David J. Portman;Matthew P. Goetz, MD;Seth A. Wander;Thomas Bachelot;Guiseppe Curigliano;Alexandre de Nonneville;Einav Nili Gal-Yam;Sarah Sammons, MD;Sherry Shen, MD;Christ Twelves;Paul V. Plourde;Senthil Damodaran
April 27th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Chemoimmunotherapy Enhanced Survival vs Chemo Alone in ES-SCLC

Chemoimmunotherapy Enhanced Survival vs Chemo Alone in ES-SCLC

Tim Cortese
April 27th 2025
Article

Patients with ES-SCLC who received immunotherapy plus chemotherapy experienced a median OS of 14.9 months vs 11.9 months with chemotherapy alone.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

Roman Fabbricatore
April 25th 2025
Article

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study

Hope S. Rugo, MD;Sara M. Tolaney, MD, MPH;Nancy Chan;Erika P. Hamilton, MD;Marina Sharifi;Kristine Rinn;Wassim McHayleh;Rinat Yerushalmi;Neelima Vidula, MD;Joyce O’Shaughnessy, MD;Guiseppe Curigliano;Javier Cortés, MD;Paula Muñoz Romero;Bartomeu Piza Vallespir;Kathy Puyana Theall;Alessandro Paoli;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
April 25th 2025
Article